2. Search Result
Search Result
Results for "

Rearranged during Transfection kinase

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116116
    Tafetinib

    SIM010603

    		 c-Kit RET VEGFR Cancer
    Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
    Tafetinib
  • HY-178061
    APS03118

    		ERK RET Cancer
    APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
    APS03118
  • HY-144422
    RET-IN-15

    		RET Cancer
    RET-IN-15 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer .
    RET-IN-15
  • HY-143545
    RET-IN-8

    		RET Cancer
    RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer .
    RET-IN-8
  • HY-174993
    FHND5071 (1H)

    		RET Cancer
    FHND5071 (1H) is a selective inhibitor targeting the RET (rearrangement during transfection) tyrosine kinase. FHND5071 (1H) is promising for research of RET-driven cancers (such as thyroid cancer, lung cancer, etc.) .
    FHND5071 (1H)
  • HY-E70776
    RET S891A Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET S891A is a mutant of RET. RET S891A Recombinant Human Active Protein Kinase is a recombinant RET S891A protein that can be used to study RET S891A-related functions .
    RET S891A Recombinant Human Active Protein Kinase
  • HY-E70778
    RET V804L Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804L is a mutant of RET. RET V804L Recombinant Human Active Protein Kinase is a recombinant RET V804L protein that can be used to study RET V804L-related functions .
    RET V804L Recombinant Human Active Protein Kinase
  • HY-E70777
    RET V804E Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804E is a mutant of RET. RET V804E Recombinant Human Active Protein Kinase is a recombinant RET V804E protein that can be used to study RET V804E-related functions .
    RET V804E Recombinant Human Active Protein Kinase
  • HY-E70859
    RET L790F Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L790F is a mutant of RET. RET L790F Recombinant Human Active Protein Kinase is a recombinant RET L790F protein that can be used to study RET L790F-related functions .
    RET L790F Recombinant Human Active Protein Kinase
  • HY-E70771
    RET L730I Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L730I is a mutant of RET. RET L730I Recombinant Human Active Protein Kinase is a recombinant RET L730I protein that can be used to study RET L730I-related functions .
    RET L730I Recombinant Human Active Protein Kinase
  • HY-E70772
    RET L730M Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L730M is a mutant of RET. RET L730M Recombinant Human Active Protein Kinase is a recombinant RET L730M protein that can be used to study RET L730M-related functions .
    RET L730M Recombinant Human Active Protein Kinase
  • HY-E70775
    RET R813Q Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R813Q is a mutant of RET. RET R813Q Recombinant Human Active Protein Kinase is a recombinant RET R813Q protein that can be used to study RET R813Q-related functions .
    RET R813Q Recombinant Human Active Protein Kinase
  • HY-E70774
    RET R749T Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R749T is a mutant of RET. RET R749T Recombinant Human Active Protein Kinase is a recombinant RET R749T protein that can be used to study RET R749T-related functions .
    RET R749T Recombinant Human Active Protein Kinase
  • HY-E70769
    RET G810R Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810R is a mutant of RET. RET G810R Recombinant Human Active Protein Kinase is a recombinant RET G810R protein that can be used to study RET G810R-related functions .
    RET G810R Recombinant Human Active Protein Kinase
  • HY-E70766
    RET E762Q Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET E762Q is a mutant of RET. RET E762Q Recombinant Human Active Protein Kinase is a recombinant RET E762Q protein that can be used to study RET E762Q-related functions .
    RET E762Q Recombinant Human Active Protein Kinase
  • HY-E70780
    RET Y791F Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y791F is a mutant of RET. RET Y791F Recombinant Human Active Protein Kinase is a recombinant RET Y791F protein that can be used to study RET Y791F-related functions .
    RET Y791F Recombinant Human Active Protein Kinase
  • HY-E70779
    RET V804M Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804M is a mutant of RET. RET V804M Recombinant Human Active Protein Kinase is a recombinant RET V804M protein that can be used to study RET V804M-related functions .
    RET V804M Recombinant Human Active Protein Kinase
  • HY-E70767
    RET G691S Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G691S is a mutant of RET. RET G691S Recombinant Human Active Protein Kinase is a recombinant RET G691S protein that can be used to study RET G691S-related functions .
    RET G691S Recombinant Human Active Protein Kinase
  • HY-E70768
    RET G810C Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810C is a mutant of RET. RET G810C Recombinant Human Active Protein Kinase is a recombinant RET G810C protein that can be used to study RET G810C-related functions .
    RET G810C Recombinant Human Active Protein Kinase
  • HY-E70773
    RET M918T Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET M918T is a mutant of RET. RET M918T Recombinant Human Active Protein Kinase is a recombinant RET M918T protein that can be used to study RET M918T-related functions .
    RET M918T Recombinant Human Active Protein Kinase
  • HY-E70781
    RET Y806H Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y806H is a mutant of RET. RET Y806H Recombinant Human Active Protein Kinase is a recombinant RET Y806H protein that can be used to study RET Y806H-related functions .
    RET Y806H Recombinant Human Active Protein Kinase
  • HY-E70770
    RET G810S Recombinant Human Active Protein Kinase

    		RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810S is a mutant of RET. RET G810S Recombinant Human Active Protein Kinase is a recombinant RET G810S protein that can be used to study RET G810S-related functions .
    RET G810S Recombinant Human Active Protein Kinase
  • HY-164482
    HG-6-63-01

    		RET Cancer
    HG-6-63-01 is a type II RET tyrosine kinase inhibitor (TKI). HG-6-63-01 also inhibits REarranged during Transfection (RET) kinase and signaling in human thyroid cancer cell lines carrying oncogenic RET alleles. HG-6-63-01 impairs phosphorylation and signalling of RET oncogenic mutants. HG-6-63-01 blunts proliferation of RET/C634R and RET/M918T-transformed fibroblasts and of RET mutant thyroid cancer cells, which is promising for research of cancers harboring oncogenic activation of RET .
    HG-6-63-01
  • HY-183729
    RET-IN-34

    		Ligands for Target Protein for PROTAC RET Endocrinology Cancer
    RET-IN-34 (Compound EV1) is a RET inhibitor with an IC50 of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma .
    RET-IN-34

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: